Pasar al contenido principal

Multifunctional Materials for Technological and Biomedical Applications

RYC-2017-22614

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Biohybrid Hydrogels for Tumoroid Culture

  • Castellote-Borrell, Miquel|||0000-0001-7703-2228
  • Merlina, Francesca|||0000-0001-5040-1687
  • Rodríguez, Adrián R.
  • Guasch, Judith|||0000-0002-3571-4711
Tumoroids are 3D in vitro models that recapitulate key features of in vivo tumors, such as their architecture - hypoxic center and oxygenated outer layer - in contrast with traditional 2D cell cultures. Moreover, they may be able to preserve the patient-specific signature in terms of cell heterogeneity and mutations. Tumoroids are, therefore, interesting tools for improving the understanding of cancer biology, developing new drugs, and potentially designing personalized therapeutic plans. Currently, tumoroids are most often established using basement membrane extracts (BME), which provide a multitude of biological cues. However, BME are characterized by a lack of well-defined composition, limited reproducibility, and potential immunogenicity as a consequence of their natural origin. Synthetic polymers can overcome these problems but lack structural and biochemical complexity, which can limit the functional capabilities of organoids. Biohybrid hydrogels consisting of both natural and synthetic components can combine their advantages and offer superior 3D culture systems. In this review, it is summarized efforts devoted to producing tumoroids using different types of biohybrid hydrogels, which are classified according to their crosslinking mechanism.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Exploring the impact of the recombinant Escherichia coli strain on defensins antimicrobial activity: BL21 versus Origami strain

  • López-Cano, Adrià
  • Martínez-Miguel, Marc
  • Guasch, Judith
  • Ratera, Imma
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
The growing emergence of microorganisms resistant to antibiotics has prompted the development of alternative antimicrobial therapies. Among them, the antimicrobial peptides produced by innate immunity, which are also known as host defense peptides (HDPs), hold great potential. They have been shown to exert activity against both Gram-positive and Gram-negative bacteria, including those resistant to antibiotics. These HDPs are classified into three categories: defensins, cathelicidins, and histatins. Traditionally, HDPs have been chemically synthesized, but this strategy often limits their application due to the high associated production costs. Alternatively, some HDPs have been recombinantly produced, but little is known about the impact of the bacterial strain in the recombinant product. This work aimed to assess the influence of the Escherichia coli strain used as cell factory to determine the activity and stability of recombinant defensins, which have 3 disulfide bonds. For that, an α-defensin [human α-defensin 5 (HD5)] and a β-defensin [bovine lingual antimicrobial peptide (LAP)] were produced in two recombinant backgrounds. The first one was an E. coli BL21 strain, which has a reducing cytoplasm, whereas the second was an E. coli Origami B, that is a strain with a more oxidizing cytoplasm. The results showed that both HD5 and LAP, fused to Green Fluorescent Protein (GFP), were successfully produced in both BL21 and Origami B strains. However, differences were observed in the HDP production yield and bactericidal activity, especially for the HD5-based protein. The HD5 protein fused to GFP was not only produced at higher yields in the E. coli BL21 strain, but it also showed a higher quality and stability than that produced in the Origami B strain. Hence, this data showed that the strain had a clear impact on both HDPs quantity and quality., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Antibiofilm surfaces based on the immobilization of a novel recombinant antimicrobial multidomain protein using self-assembled monolayers

  • Kyvik, Adriana R.
  • Roca, Ramon
  • Mayolo-Deloisa, Karla
  • Rodriguez Rodriguez, Xavier
  • Martinez-Miguel, Marc
  • Martos, Marta
  • Köber, Mariana
  • Ventosa, Nora
  • Veciana, Jaume
  • Guasch, Judith
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
  • Ratera, Imma
The constant increase of microorganisms resistant to antibiotics has been classified as a global health emergency, which is especially challenging when biofilms are formed. Herein, novel biofunctionalized gold surfaces with the antimicrobial multidomain recombinant protein JAMF1, both in the soluble form and nanostructured as nanoparticles, were developed. The interaction between His-tag termination of the protein and a nitriloacetic acid–Ni complex formed on mixed self-assembled monolayers (mixed SAMs) was exploited. The obtained antibiofilm surfaces based on the immobilization of the novel JAMF1 protein using self-assembled monolayers were characterized using a multi-technique approach including: cyclic voltammetry, X-ray photoelectron spectroscopy, atomic force microscopy and fluorescence, proving that the modification and immobilization of JAMF1 were successfully done. The antibiofilm activity against Escherichia coli and carbapenem-resistant Klebsiella pneumoniae showed that the immobilized antimicrobial proteins were able to reduce biofilm formation of both microorganisms. This strategy opens up new possibilities for controlled biomolecule immobilization for fundamental biological studies and biotechnological applications, at the interface of materials science and molecular biology., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

CCL21-loaded 3D hydrogels for T cell expansion and differentiation

  • Pérez del Río, Eduardo
  • Santos, Fabião
  • Rodriguez Rodriguez, Xavier
  • Martínez-Miguel, Marc
  • Roca-Pinilla, Ramon
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
  • Veciana, Jaume
  • Spatz, Joachim P.
  • Ratera, Imma
  • Guasch, Judith
Recent achievements in the field of immunotherapy, such as the development of engineered T cells used in adoptive cell therapy, are introducing more efficient strategies to combat cancer. Nevertheless, there are still many limitations. For example, these T cells are challenging to manufacture, manipulate, and control. Specifically, there are limitations in producing the large amounts of therapeutic T cells needed for these therapies in a short period of time and in an economically viable manner. In this study, three-dimensional (3D) poly(ethylene) glycol (PEG) hydrogels covalently combined with low molecular weight heparin are engineered to resemble the lymph nodes, where T cells reproduce. In these hydrogels, PEG provides the needed structural and mechanical properties, whereas heparin is used as an anchor for the cytokine CCL21, which is present in the lymph nodes, and can affect cell migration and proliferation. The 3D structure of the hydrogel in combination with its loading capacity result in an increased primary human CD4+ T cell proliferation compared to the state-of-the-art expansion systems consisting of artificial antigen presenting cells. Thus, we present a new tool for adoptive cell therapy to help achieving the large numbers of cells required for therapy of selected phenotypes targeted against cancer cells, by mimicking the lymph nodes., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins

  • López-Cano, Adrià
  • Ferrer-Miralles, Neus
  • Sánchez, Julieta
  • Carratalá, Jose Vicente
  • Rodriguez Rodriguez, Xavier
  • Ratera, Imma
  • Guasch, Judith
  • Pich, Oscar Q.
  • Bierge, Paula
  • Garcia-de-la-Maria, Cristina
  • Miro, Jose M.
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel generation of tailored antimicrobial drugs based on recombinant multidomain proteins

  • López Cano, Adrià
  • Ferrer Miralles, Neus
  • Sánchez, Julieta
  • Carratalá, Jose Vicente
  • Rodríguez Rodríguez, Xavier
  • Ratera, Immaculada
  • Guasch, Judit
  • Pich, Oscar Q.
  • Bierge, Paula
  • Garcia de la María, Cristina
  • Miro, Jose M.
  • García Fruitós, Elena
  • Arís, Anna
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means., This work was funded by the Ministerio de Ciencia, Innovación y Universidades grants (PID2019-107298RB-C21/AEI/10.13039/501100011033; PID2019-105622RBI00; PID2020-115296RA-I00; RYC-2017-22614), by Marató de TV3 foundation (201812-30-31-32-33). We also thank the Instituto de Salud Carlos III (ISCIII) through the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). The authors are also indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. JMS is supported with a María Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (“Financed by European Union-Next GenerationEU”). AL-C received a pre-doctoral fellowship from Generalitat de Catalunya (FI-AGAUR) and EG-F a post-doctoral fellowship from INIA (DOC-INIA). J.G. acknowledges financial support from the Max Planck Society through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy” in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). ICMAB acknowledges support from the MICINN through the ‘‘Severo Ochoa’’ Program for Centers of Excellence in R&D (CEX2019-000917-S). JMM received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–23., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2019-000917-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Antibiofilm surfaces based on the immobilization of a novel recombinant antimicrobial multidomain protein using self-assembled monolayers

  • Kyvik, Adriana R.
  • Roca, Ramon
  • Mayolo-Deloisa, Karla
  • Rodriguez Rodriguez, Xavier
  • Martinez-Miguel, Marc
  • Martos, Marta
  • Köber, Mariana
  • Ventosa, Nora
  • Veciana, Jaume
  • Guasch, Judith
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
  • Ratera, Imma
The constant increase of microorganisms resistant to antibiotics has been classified as a global health emergency, which is especially challenging when biofilms are formed. Herein, novel biofunctionalized gold surfaces with the antimicrobial multidomain recombinant protein JAMF1, both in the soluble form and nanostructured as nanoparticles, were developed. The interaction between His-tag termination of the protein and a nitriloacetic acid–Ni complex formed on mixed self-assembled monolayers (mixed SAMs) was exploited. The obtained antibiofilm surfaces based on the immobilization of the novel JAMF1 protein using self-assembled monolayers were characterized using a multi-technique approach including: cyclic voltammetry, X-ray photoelectron spectroscopy, atomic force microscopy and fluorescence, proving that the modification and immobilization of JAMF1 were successfully done. The antibiofilm activity against Escherichia coli and carbapenem-resistant Klebsiella pneumoniae showed that the immobilized antimicrobial proteins were able to reduce biofilm formation of both microorganisms. This strategy opens up new possibilities for controlled biomolecule immobilization for fundamental biological studies and biotechnological applications, at the interface of materials science and molecular biology., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins

  • López-Cano, Adrià
  • Ferrer-Miralles, Neus
  • Sánchez, Julieta
  • Carratalá, Jose Vicente
  • Rodriguez Rodriguez, Xavier
  • Ratera, Imma
  • Guasch, Judith
  • Pich, Oscar Q.
  • Bierge, Paula
  • Garcia-de-la-Maria, Cristina
  • Miro, Jose M.
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exploring the impact of the recombinant Escherichia coli strain on defensins antimicrobial activity: BL21 versus Origami strain

  • López-Cano, Adrià
  • Martínez-Miguel, Marc
  • Guasch, Judith
  • Ratera, Imma
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
The growing emergence of microorganisms resistant to antibiotics has prompted the development of alternative antimicrobial therapies. Among them, the antimicrobial peptides produced by innate immunity, which are also known as host defense peptides (HDPs), hold great potential. They have been shown to exert activity against both Gram-positive and Gram-negative bacteria, including those resistant to antibiotics. These HDPs are classified into three categories: defensins, cathelicidins, and histatins. Traditionally, HDPs have been chemically synthesized, but this strategy often limits their application due to the high associated production costs. Alternatively, some HDPs have been recombinantly produced, but little is known about the impact of the bacterial strain in the recombinant product. This work aimed to assess the influence of the Escherichia coli strain used as cell factory to determine the activity and stability of recombinant defensins, which have 3 disulfide bonds. For that, an α-defensin [human α-defensin 5 (HD5)] and a β-defensin [bovine lingual antimicrobial peptide (LAP)] were produced in two recombinant backgrounds. The first one was an E. coli BL21 strain, which has a reducing cytoplasm, whereas the second was an E. coli Origami B, that is a strain with a more oxidizing cytoplasm. The results showed that both HD5 and LAP, fused to Green Fluorescent Protein (GFP), were successfully produced in both BL21 and Origami B strains. However, differences were observed in the HDP production yield and bactericidal activity, especially for the HD5-based protein. The HD5 protein fused to GFP was not only produced at higher yields in the E. coli BL21 strain, but it also showed a higher quality and stability than that produced in the Origami B strain. Hence, this data showed that the strain had a clear impact on both HDPs quantity and quality., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CCL21-loaded 3D hydrogels for T cell expansion and differentiation

  • Pérez del Río, Eduardo
  • Santos, Fabião
  • Rodriguez Rodriguez, Xavier
  • Martínez-Miguel, Marc
  • Roca-Pinilla, Ramon
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
  • Veciana, Jaume
  • Spatz, Joachim P.
  • Ratera, Imma
  • Guasch, Judith
Recent achievements in the field of immunotherapy, such as the development of engineered T cells used in adoptive cell therapy, are introducing more efficient strategies to combat cancer. Nevertheless, there are still many limitations. For example, these T cells are challenging to manufacture, manipulate, and control. Specifically, there are limitations in producing the large amounts of therapeutic T cells needed for these therapies in a short period of time and in an economically viable manner. In this study, three-dimensional (3D) poly(ethylene) glycol (PEG) hydrogels covalently combined with low molecular weight heparin are engineered to resemble the lymph nodes, where T cells reproduce. In these hydrogels, PEG provides the needed structural and mechanical properties, whereas heparin is used as an anchor for the cytokine CCL21, which is present in the lymph nodes, and can affect cell migration and proliferation. The 3D structure of the hydrogel in combination with its loading capacity result in an increased primary human CD4+ T cell proliferation compared to the state-of-the-art expansion systems consisting of artificial antigen presenting cells. Thus, we present a new tool for adoptive cell therapy to help achieving the large numbers of cells required for therapy of selected phenotypes targeted against cancer cells, by mimicking the lymph nodes., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins

  • López-Cano, Adrià
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Rodriguez Rodriguez, Xavier
  • Ratera Bastardas, Imma|||0000-0002-1464-9789
  • Guasch, Judith|||0000-0002-3571-4711
  • Pich, Oscar Q.|||0000-0003-3561-630X
  • Bierge, Paula|||0000-0003-0917-3445
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Miró, José M.|||0000-0001-8057-7755
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means.